Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1848.5000 46.10 (2.56%)

NSE Feb 25, 2026 15:49 PM

44.66% Gain from 52W Low

Volume: 92,312

Gland Pharma Ltd.

06 Aug 2025

1848.50

2.56%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.